529 related articles for article (PubMed ID: 16430398)
1. Breast cancer in limited-resource countries: treatment and allocation of resources.
Eniu A; Carlson RW; Aziz Z; Bines J; Hortobágyi GN; Bese NS; Love RR; Vikram B; Kurkure A; Anderson BO;
Breast J; 2006; 12 Suppl 1():S38-53. PubMed ID: 16430398
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines.
Anderson BO; Shyyan R; Eniu A; Smith RA; Yip CH; Bese NS; Chow LW; Masood S; Ramsey SD; Carlson RW
Breast J; 2006; 12 Suppl 1():S3-15. PubMed ID: 16430397
[TBL] [Abstract][Full Text] [Related]
3. How to make the best use of limited resources in breast cancer treatment--experiences in Bosnia & Herzegovina.
Obralić N; Beslija S
J BUON; 2006; 11(1):21-9. PubMed ID: 17318948
[TBL] [Abstract][Full Text] [Related]
4. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation.
Eniu A; Carlson RW; El Saghir NS; Bines J; Bese NS; Vorobiof D; Masetti R; Anderson BO;
Cancer; 2008 Oct; 113(8 Suppl):2269-81. PubMed ID: 18837019
[TBL] [Abstract][Full Text] [Related]
5. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer in limited-resource countries: health care systems and public policy.
Anderson BO; Yip CH; Ramsey SD; Bengoa R; Braun S; Fitch M; Groot M; Sancho-Garnier H; Tsu VD;
Breast J; 2006; 12 Suppl 1():S54-69. PubMed ID: 16430399
[TBL] [Abstract][Full Text] [Related]
7. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
8. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Mamounas EP
Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
[TBL] [Abstract][Full Text] [Related]
9. Treatment of breast cancer in countries with limited resources.
Carlson RW; Anderson BO; Chopra R; Eniu AE; Jakesz R; Love RR; Masetti R; Schwartsmann G;
Breast J; 2003; 9 Suppl 2():S67-74. PubMed ID: 12713499
[TBL] [Abstract][Full Text] [Related]
10. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer in limited-resource countries: diagnosis and pathology.
Shyyan R; Masood S; Badwe RA; Errico KM; Liberman L; Ozmen V; Stalsberg H; Vargas H; Vass L;
Breast J; 2006; 12 Suppl 1():S27-37. PubMed ID: 16430396
[TBL] [Abstract][Full Text] [Related]
12. Guideline implementation for breast healthcare in low- and middle-income countries: breast healthcare program resource allocation.
Harford J; Azavedo E; Fischietto M;
Cancer; 2008 Oct; 113(8 Suppl):2282-96. PubMed ID: 18837020
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries.
El Saghir NS; Eniu A; Carlson RW; Aziz Z; Vorobiof D; Hortobagyi GN;
Cancer; 2008 Oct; 113(8 Suppl):2315-24. PubMed ID: 18837023
[TBL] [Abstract][Full Text] [Related]
14. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
15. [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):111-3. PubMed ID: 20087042
[TBL] [Abstract][Full Text] [Related]
16. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
17. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
18. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
19. Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
Beal K; Hudis C; Norton L; Wagman R; McCormick B
Breast J; 2005; 11(5):317-20. PubMed ID: 16174151
[TBL] [Abstract][Full Text] [Related]
20. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
